Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value (CRBP)
CUSIP: 21833P301
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, $0.0001 par value
- Shares outstanding
- 17,685,185
- Total 13F shares
- 13,244,299
- Share change
- +4,456,167
- Total reported value
- $107,809,776
- Put/Call ratio
- 0%
- Price per share
- $8.14
- Number of holders
- 100
- Value change
- +$34,670,749
- Number of buys
- 52
- Number of sells
- 29
Quarterly Holders Quick Answers
What is CUSIP 21833P301?
CUSIP 21833P301 identifies CRBP - Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 21833P301:
Top shareholders of CRBP - Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP |
13F
13D/G
3/4/5
|
Company · 10%+ Owner |
13%
from 13D/G
|
2,375,000
|
$30,043,750 | — | 30 Sep 2025 | |
| ORBIMED ADVISORS LLC |
13F
13D/G
|
Company · OrbiMed Capital LLC |
5.9%
from 13D/G
|
1,172,287
|
$14,829,431 | — | 30 Sep 2025 | |
| Octagon Capital Advisors LP |
13F
13D/G
|
Company |
5.4%
from 13D/G
|
1,115,000
|
$14,104,750 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13D/G
|
Kenneth Griffin |
5.3%
|
980,610
|
$12,405,011 | $0 | 04 Nov 2025 | |
| Aberdeen Group plc |
13D/G
13F
|
Company |
7.5%
|
1,321,750
|
$10,759,045 | $0 | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
13D/G
|
Company · The Vanguard Group |
4.9%
from 13D/G
|
612,030
|
$7,742,180 | — | 30 Sep 2025 | |
| Rachael Louise Brake |
3/4/5
|
Chief Scientific Officer |
—
class O/S missing
|
1,400,000
|
$6,958,000 | — | 13 Feb 2023 | |
| Craig Stuart Millian |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
934,645
|
$4,645,186 | — | 13 Feb 2023 | |
| Prosight Management, LP |
13F
|
Company |
1.9%
|
343,400
|
$4,344,010 | — | 30 Sep 2025 | |
| Exome Asset Management LLC |
13F
|
Company |
1.3%
|
229,962
|
$2,909,019 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
2.9%
from 13D/G
|
226,898
|
$2,870,258 | — | 30 Sep 2025 | |
| COMERICA BANK |
13F
|
Company |
1.1%
|
200,001
|
$2,530,013 | — | 30 Sep 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
1.1%
|
192,000
|
$2,428,800 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.88%
|
154,842
|
$1,958,752 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.77%
|
136,429
|
$1,725,827 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.72%
|
127,731
|
$1,616,489 | — | 30 Sep 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.72%
|
127,520
|
$1,613,128 | — | 30 Sep 2025 | |
| HighVista Strategies LLC |
13F
|
Company |
0.67%
|
118,027
|
$1,493,041 | — | 30 Sep 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.61%
|
107,200
|
$1,356,080 | — | 30 Sep 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.58%
|
102,509
|
$1,296,738 | — | 30 Sep 2025 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. |
13F
|
Company |
0.49%
|
85,826
|
$1,085,699 | — | 30 Sep 2025 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.48%
|
85,347
|
$1,079,640 | — | 30 Sep 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.47%
|
83,819
|
$1,059,000 | — | 30 Sep 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.39%
|
69,625
|
$880,756 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.39%
|
69,246
|
$875,962 | — | 30 Sep 2025 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.38%
|
66,984
|
$847,348 | — | 30 Sep 2025 | |
| Velan Capital Investment Management LP |
13F
|
Company |
0.34%
|
61,000
|
$771,650 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.34%
|
59,496
|
$752,624 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.33%
|
58,151
|
$735,610 | — | 30 Sep 2025 | |
| SUPERSTRING CAPITAL MANAGEMENT LP |
13F
|
Company |
0.33%
|
57,644
|
$729,197 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.31%
|
55,092
|
$696,914 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.31%
|
54,661
|
$691,461 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.19%
|
33,352
|
$421,903 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.15%
|
27,231
|
$344,473 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.15%
|
26,457
|
$334,681 | — | 30 Sep 2025 | |
| Baker Avenue Asset Management, LP |
13F
|
Company |
0.14%
|
24,191
|
$306,016 | — | 30 Sep 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.13%
|
23,418
|
$296,238 | — | 30 Sep 2025 | |
| Mariner, LLC |
13F
|
Company |
0.12%
|
20,840
|
$263,626 | — | 30 Sep 2025 | |
| Alan F. Holmer |
3/4/5
|
Director |
—
mixed-class rows
|
32,458
mixed-class rows
|
$254,268 | — | 30 May 2025 | |
| AlphaQuest LLC |
13F
|
Company |
0.11%
|
18,994
|
$240,274 | — | 30 Sep 2025 | |
| Atle Fund Management AB |
13F
|
Company |
0.99%
|
175,582
|
$235,802 | — | 30 Sep 2025 | |
| SIMPLEX TRADING, LLC |
13F
|
Company |
0.1%
|
17,950
|
$227,000 | — | 30 Sep 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.09%
|
15,236
|
$193,000 | — | 30 Sep 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.07%
|
12,572
|
$160,000 | — | 30 Sep 2025 | |
| Trexquant Investment LP |
13F
|
Company |
0.07%
|
12,165
|
$153,887 | — | 30 Sep 2025 | |
| Avery W. Catlin |
3/4/5
|
Director |
—
mixed-class rows
|
7,133
mixed-class rows
|
$144,332 | — | 30 May 2024 | |
| Rachelle Suzanne Jacques |
3/4/5
|
Director |
—
mixed-class rows
|
26,366
mixed-class rows
|
$140,135 | — | 30 May 2025 | |
| Yong Ben |
3/4/5
|
Director |
—
mixed-class rows
|
26,366
mixed-class rows
|
$140,135 | — | 30 May 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.06%
|
10,627
|
$134,432 | — | 30 Sep 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.06%
|
10,200
|
$129,030 | — | 30 Sep 2025 |
Institutional Holders of Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value (CRBP) as of Q4 2025
As of 31 Dec 2025,
Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value (CRBP) was held by
100 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
13,244,299 shares.
The largest 10 holders included
Cormorant Asset Management, LP, ORBIMED ADVISORS LLC, Aberdeen Group plc, Octagon Capital Advisors LP, VANGUARD GROUP INC, CITADEL ADVISORS LLC, Prosight Management, LP, ARMISTICE CAPITAL, LLC, Stonepine Capital Management, LLC, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
100
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
79
Q4 2025 holders
100
Holder diff
21
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.